In the TANGO study, overall adverse events were comparable across both arms at 48 weeks 2
Any drug related AE, grades 2-5 and AEs leading to withdrawal were higher in the Dovato arm vs the TAF-containing regimen arm. This is expected since the majority of patients were switching to a new regimen after suppression on their previous regimen for approx. 3 years (median).
- Minimal changes in overall mean weight. Change from baseline was ≈0.8 kg over 48 weeks in both treatment arms. 1
METABOLIC BIOMARKERS AT 48 WEEKS
INCREASED PROPORTIONS OF PATIENTS WITH OPTIMAL TC/HDL RATIO (<3.5)
Classified by NCEP category as 'Green' (<3.5) in the Dovato arm, while remaining constant in the TAF-containing regimen arm vs baseline 2
- Cahn P, Sierra Madero J, Arribas J, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infections: 96-week results from the GEMINI studies, Presented at: International AIDS Conference; July 21-24, 2019; Mexico City, Mexico, Slides WEAB0404LB.
- van Wyk J, Ajana F, Bisshop F, et al. Switching to DTG/3TC fixed-dose combination (FDC) is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO study). Presented at: International AIDS Conference; July 21-24, 2019; Mexico City. Slides WEAB0403LB.
- Data on file. GEMINI-1 and GEMINI-2 96-week renal and urinary disorders/adverse events; REF-31232. ViiV Healthcare group of companies. Research Triangle Park, NC.